| Literature DB >> 31817133 |
Muhammad Faiq Abdullah1,2, Tamrin Nuge3, Andri Andriyana3,4, Bee Chin Ang1,3, Farina Muhamad5.
Abstract
The key attributes of core-shell fibers are their ability to preserve bioactivity of incorporated-sensitive biomolecules (such as drug, protein, and growth factor) and subsequently control biomolecule release to the targeted microenvironments to achieve therapeutic effects. Such qualities are highly favorable for tissue engineering and drug delivery, and these features are not able to be offered by monolithic fibers. In this review, we begin with an overview on design requirement of core-shell fibers, followed by the summary of recent preparation methods of core-shell fibers, with focus on electrospinning-based techniques and other newly discovered fabrication approaches. We then highlight the importance and roles of core-shell fibers in tissue engineering and drug delivery, accompanied by thorough discussion on controllable release strategies of the incorporated bioactive molecules from the fibers. Ultimately, we touch on core-shell fibers-related challenges and offer perspectives on their future direction towards clinical applications.Entities:
Keywords: core–shell fibers; drug delivery; release strategy; scaffolds; tissue engineering
Year: 2019 PMID: 31817133 PMCID: PMC6960548 DOI: 10.3390/polym11122008
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1(a) Scheme illustrating two different design approaches of core–shell fibers and (b) their role in multiple biomolecules delivery with controllable release profiles.
Selected combinations of core–shell fibers materials for various tissue engineering and drug delivery applications.
| Core Material | Shell Material | Bioactive Molecules | Fabrication Technique | In vitro/in vivo Testing | Prospective Application | Ref. |
|---|---|---|---|---|---|---|
| PLA | PNIPAAM | Combreta-statin A4 | Single electrospinning plus UV photopolymerization | Mouse fibroblast cells (L-929) | Biomaterial | [ |
| Gelatin | Chitosan | na | Coaxial electrospinning | Human osteoblast cell line (MG-63) | [ | |
| na | PCL | Platelet lyophylisates | Emulsion centrifugal spinning | Human osteosarcoma cells (MG-63), murine 3T3 fibroblasts cells | [ | |
| PVP | PLGA | Naringin, metronidazole | Coaxial electrospinning | MC3T3-E1 cells | Guided tissue regeneration | [ |
| PCL | Zein | Metronidazole | Coaxial electrospinning | L929 cells | [ | |
| PLGA/HA | Collagen | Amoxicillin | Coaxial electrospinning | HDF | [ | |
| PGS | PLA/PEO | na | Coaxial electrospinning | HUASMCs | Soft/hard tissue engineering | [ |
| PCL | Collagen | na | Electrohydrodynamic plus bioprinting | Mouse preosteoblast (MC3T3-E1) cells | [ | |
| na | Collagen/chitosan/PLCL | Heparin | Coaxial electrospinning | PIECs | Vascular tissue engineering, vascular graft | [ |
| PLLA/PEO | PLCL/PEO | na | Coaxial electrospinning | HUASMCs, HUVECs | [ | |
| na | PLCL/collagen | Heparin, Salvianolic acid B | Coaxial electrospinning | HUVECs/Male Sprague Dawley rats | [ | |
| na | PLGA | LBP | Coaxial electrospinning | Rat pheochromocytoma (PC12) cells | Nerve tissue engineering | [ |
| na | PLGA, PDLLA | NGF, GDNF | Emulsion electrospinning | PC12 cells | [ | |
| PLLA | PGS | na | Single electrospinning plus phase separation | Hypothalamus A59 nerve cell | [ | |
| SF | PLA | NGF | Coaxial electrospinning | Rat PC12 cells | Neural tissue engineering | [ |
| na | PDO/ collagen | Laminin | Magnetic-field assisted coaxial electrospinning | HT-22 mouse hippocampal neuronal cells | [ | |
| PLA | CA | Citalopram | Wet coaxial electrospinning | Rat Schwann cells/Male Wistar rats | [ | |
| PEG | PLGA | FGF-2 | Coaxial electrospinning | PC12 cells/Male Wistar rats | Spinal cord tissue engineering | [ |
| PCL | CMCh/ PVA | Zinc-curcumin complex | Coaxial electrospinning | Mouse fibroblast cells (L929), MG-63 human osteoblast cells | Bone tissue engineering | [ |
| TSF/CaOH/H3PO4 | TSF | na | Coaxial electrospinning | Human osteosarcoma MG-63 cells | [ | |
| PCL | PLA/HA | BMP-2 | Coaxial electrospinning | hMSCs | [ | |
| na | SF/chitosan/nHAP | BMP-2 | Coaxial electrospinning | BMMSCs/Female nude mice | [ | |
| na | PLGA/PCL | BMP-2 | Coaxial electrospinning | rADSCs | [ | |
| na | SF/PLCL | Icariin | Coaxial electrospinning | BMMSCs/Male Sprague Dawley rats | Guided bone regeneration | [ |
| na | SF/P(LLA-CL) | rhBMP-2, IGF-1 | Coaxial electrospinning | BMMSCs | [ | |
| PCL/SF/PANI/CSA | PEGS-M | na | Single electrospinning plus UV irradiation | C2C12 mouse myoblasts | Skeletal muscle tissue engineering | [ |
| CNTs | PELA | na | Coaxial electrospinning | Primary cardiomyocytes of neonatal rat | Cardiac tissue engineering | [ |
| PCL | ShHL | na | Coaxial electrospinning | HUVECs, mouse fibroblast cells L929 | [ | |
| CNTs | PELA | na | Coaxial electrospinning with micropatterned collector | CMs, ECs, CFs | [ | |
| PLA | Gelatin | na | Coaxial electrospinning | Rat chondrocyte, BMMSCs | Cartilage tissue engineering | [ |
| na | P(LLA-CL)/collagen | Kartogenin | Coaxial electrospinning | BMMSCs | Tracheal cartilage regeneration | [ |
| na | P(LLA-CL)/collagen | rhTGF-β3 | Coaxial electrospinning | Human umbilical cord WMSCs | [ | |
| Zein prola-mine | Ethanol/DI water | GLSP | Coaxial electrospinning | Fibroblast L929 cells | Skin tissue engineering | [ |
| PCL | PVA/ gelatin | Salvianolic acid B, bromelain | Coaxial electrospinning | Human epidermal keratinocytes, ECs/Female Wistar albino rats | [ | |
| na | SF/PEO | Dexametha-sone | Emulsion electrospinning | PHAECs | [ | |
| Poloxa-mer 188 | PCL | Platelet lyophilisate | Needleless emulsion electrospin-ning, centrifugal force spinning | Murine XB2 cell line (keratinocytes), 3T3-A31 cell line (fibroblasts) | Dermal tissue engineering | [ |
| PVP | PCL/ PVP | Sulfo-rhodamine B | Solution blow spinning | Human epidermal keratinocytes | [ | |
| PCL | PCL | na | Mechanical stretching | Human tenocytes/Male micropigs | Tendon tissue regeneration | [ |
| PNIPA-AM | EC | Ketoprofen | Coaxial electrospinning | Mouse fibroblast cells (L929) | Advanced drug delivery | [ |
| PVP/GO | PCL | Vancomycin hydrochloride | Coaxial electrospinning | L929 fibroblast cells | [ | |
| Hyalu-ronic acid | PCL | Ampicillin, Bay 11-7082, pirfenidone | Emulsion electrospinning plus electrospraying | Mouse embryonic fibroblasts (NIH3T3)/C57BL/6 mice | Drug eluting construct/stent | [ |
| Gum traga-canth | PLGA | TCH | Coaxial electrospinning | HDF | Drug delivery-periodontal diseases | [ |
| Chitosan | PCL | Ferulic acid, resveratrol | Coaxial electrospinning | Human epidermal keratinocytes/Female albino Wistar rats | Drug delivery-acute wounds | [ |
| na | PLCL | EDTA, SC | Coaxial electrospinning | PIECs | Drug delivery-gallstone dissolution | [ |
| PEO | Zein | Gallic acid | Coaxial electrospinning | Human gallbladder cancer cell lines (GB-d1 and NOZ) | Drug delivery-gallbladder cancer cells | [ |
| PVA | SA/ PEO | Quercetin | Coaxial electrospinning | Colon cancer cells (Caco-2), mucosal cells (CCC-HIE-2) | Drug delivery-colon cancer | [ |
| PES | PNIPAAM-co-Am | Curcumin | Single electrospinning plus coating (radical copolymerization) | Colon cancer cells HCT116 | [ | |
| PVA | Gelatin/genipin | Doxorubicin | Coaxial electrospinning | 4T1 cells (tumor cells), NIH 3T3 fibroblasts (normal cells)/4T1 tumor bearing nude mice | Cancer therapy | [ |
| PCL | PCL/gelatin | Resveratrol, siRNA | Coaxial electrospinning | Erythroleukeia cell (K562) | [ | |
| PLGA/ PCL | Gelatin | Doxorubicin | Coaxial electrospinning | Mouse melanoma cell line (B16)/Female C57BL/6 mice | Skin cancer treatment | [ |
| SF | PLCL/PEO | CTGF, FGF-2 | Coaxial electrospinning | rMSCs | Mesenchymal stem cell trans-plantation | [ |
| PVP | EC | Maraviroc | Coaxial electrospinning | TZM-bL cells | HIV prevention | [ |
Abbreviations: BMMSCs, bone marrow-derived mesenchymal stem cells; BMP-2, bone morphogenetic protein-2; CA, cellulose acetate; CFs, cardiac fibroblasts; CMCh, carboxymethyl chitosan; CMs, cardiomyocytes; CNTs, carbon nanotubes; CSA, camphorsulfonic acid; CTGF, connective tissue growth factor; DI, deionized; EC, ethyl cellulose; ECs, endothelial cells; EDTA, ethylene diamine tetraacetic acid; FGF-2, fibroblast growth factor-2; GDNF, glial cell line-derived neurotrophic factor; GLSP, ganoderma lucidum spore polysaccharide; GO, graphene oxide; HA, hydroxyapatite; HDF, human dermal fibroblasts; HIV, human immunodeficiency virus; hMSCs, human mesenchymal stem cells; HUASMCs, human umbilical artery smooth muscle cells; HUVECs, human umbilical vein endothelial cells; IGF-1, insulin growth factor-1; LBP, lycium barbarum polysaccharide; na, not applicable; NGF, nerve growth factor; nHAP, nanohydroxyapatite; PANI, polyaniline; PCL, poly(ɛ-caprolactone); PDLLA, poly(d,l-lactic acid); PDO, polydioxanone; PEG, poly(ethylene glycol); PEGS-M, poly(ethylene glycol)–co–poly(glycerol sebacate); PELA, poly(ethylene glycol)-poly(d,l-lactide); PEO, poly(ethylene oxide); PES, polyethersulfone; PGS, poly(glycerol sebacate); PHAECs, porcine hip artery endothelial cells; PIECs, porcine iliac endothelial cells; PLA, poly(lactic acid); PLCL, poly(lactide–co–ɛ-caprolactone); PLGA, poly(d,l-lactic–co–glycolic acid); PLLA, poly(l-lactic acid); P(LLA-CL), poly(l-lactide–co–caprolactone); PNIPAAM, poly(N-isopropylacrylamide); PVA, poly(vinyl alcohol); PVP, polyvinyl pyrrolidone; rADSCs, rat adipose-derived stem cells; rhBMP-2, recombinant human bone morphogenetic protein-2; rhTGF-β3, recombinant human transforming growth factor-β3; rMSCs, recombinant mesenchymal stem cells; SA, sodium alginate; SC, sodium cholate; SF, silk fibroin; ShHL, sulfated hydrolyzed halomonas levan; siRNA, small interfering ribonucleic acid; TCH, tetracycline hydrochloride; TSF, tussah silk fibroin; UV, ultraviolet; WMSCs, Wharton’s jelly mesenchymal stem cells.
Figure 2(a) Digital and SEM images of fibrous mats with Hc-, Rect-, and Sq-patterns for CM and EC loadings and fibers coated on patterned-mats strut. (b) Sarcomeric α-actinin, troponin I and connexin-43 quantification analyses from Western blot image band densities (relative protein levels were normalized against β-actin signals, n = 3; *: p < 0.05 compared to other groups). (c) SEM images of cellular morphologies post 15-day CMs coculture on aligned, Hc-, Rect-, and Sq-patterned fibrous mats. Reproduced from the work in [32]. Copyright 2017 with permission from Elsevier.
Figure 3(a) Schematic diagram of modified triaxial electrospinning setup. Digital images of (b) the triaxial concentric spinneret and (c) the droplet shape before and after 15 kV voltage was supplied. Reprinted from the work in [110]. Copyright 2019 with permission from Elsevier. (d) Schematic design of needleless coaxial spinneret and (e) digital image of bilayer polymer jets on needleless spinneret. Reprinted from the work in [95]. Copyright 2017 with permission from Elsevier.
Figure 4(a) Scheme illustrating the preparation of core–shell and island-like fibers through single electrospinning plus in situ phase separation. SEM and TEM images of core–shell and island-like structures are shown in A1, A2, and A3, A4, respectively. (b) SEM and laser scanning confocal microscopy (LSCM) micrographs of mouse preosteoblasts after 48 h cultivation on pure PLA fibers (B1, B2), PLA/chitosan core–shell fibers (B3, B4), and PLA/chitosan island-like fibers (B5, B6). Prior LSCM testing, mouse preosteoblasts were stained with tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin and 4′,6-diamidino-2-phenylindole (DAPI). All LSCM micrographs are at 400× magnification. Reproduced from [125]. Copyright 2017 with permission from American Chemical Society.
Figure 5Schematic illustration of core–shell fibers preparation via single electrospinning plus UV photocross-linking. Reprinted from the work in [68]. Copyright 2015 with permission from American Chemical Society.
Figure 6(a) Schematic illustration of P4VP/PEG core–shell nanofibers preparation via highly kinetics-controlled DNA/polymer self-assembly. (b) TEM and (c) FESEM micrographs of 1,4-dibromobutane-cross-linked P4VP/PEG core–shell nanofibers fabricated through self-assembly of PEG113–b–P4VP67 block copolymers with calf thymus DNA. Reprinted from the work in [131]. Copyright 2018 with permission from American Chemical Society.
Figure 7(a) Schematic diagram portraying the coaxial spinneret (left) and bioprinter setup (right). (b) Fluorescent-labeled cells in core–shell bioprinted 3D lattice (1 mm scale bar). (c) Digital image of 20-layer bioprinted construct (10 mm scale bar). Reprinted from the work in [45]. Copyright 2017 with permission from Wiley-VCH.
Figure 8(a) Schematic illustration of emulsion preparation process. (b) Digital images of centrifugal spinning setup. Reprinted from the work in [50]. Copyright 2017 with permission from Royal Society of Chemistry.
Summary of working principle, advantage, and limitation of remaining fabrication strategies of core–shell fibers.
| Fabrication Technique | Working Principle | Advantage | Limitation | Ref. |
|---|---|---|---|---|
| Microfluidics | - Use special plate with slit channel where core flow channel is flanked by sheath flow channel | - Avoid use of high voltage | - Fiber size depends on channel diameter (currently at micro-size) | [ |
| Solution blow spinning | - Require use of triaxial nozzle; for core and intermediate polymer, and compressed air (as shell fluid) | - Avoid electrostatic drive-force and conductive collector | - Large fiber diameter (∼1 µm) | [ |
| Coaxial airbrush | - Employing almost similar principle as solution blow spinning | - Avoid use of high voltage and conductive collector | - Relatively large average diameter of fiber (500 nm–1 µm) | [ |
List of reported sensitive bioactive molecules and respective core–shell fibers systems employed to preserve them.
| Bioactive Molecule | Limitation | Core System | Shell System | Ref. | |
|---|---|---|---|---|---|
| Drug | Curcumin | Limited bioavailability due to poor absorption and rapid metabolism in body | Curcumin in absolute ethanol | PVA/chitosan in water/glacial acetic acid | [ |
| Resveratrol | Quickly metabolized and eliminated from body system (in form of sulfated and monoglucuronide derivatives) | Resveratrol/chitosan in acetic acid (90%) | PCL in DCM/ethanol | [ | |
| Mycopheno-lic acid | Rapid decrease of concentration in vivo | Mycophenolic acid/PCL in TFE/DCM | PCL in TFE/DCM | [ | |
| Tetracycline hydrochlo-ride | Vulnerable to oxidative degradation | Tetracycline hydrochloride/PVP in ethanol | PCL in acetic acid | [ | |
| Berberine hydrochlo-ride | Low bioavailability post oral administration due to rapid decrease of plasma concentration | Berberine hydrochloride/ethylcellulose in acetone/ethanol | Glycerol monostearate in DCM/DMAc | [ | |
| Growth factor | VEGF | Short half-life (less than 1 h) | VEGF in BSA | P(LLA-CL)/collagen/elastin in HFIP | [ |
| Heparin/VEGF in distilled water | P(LLA-CL) in DCM | [ | |||
| PEDF | Short half-life in vivo and chemically unstable | PEDF/ PEG in DI water | PCL in DMF/chloroform | [ | |
| NGF, GDNF | Potential denaturation and destabilization when in contact with organic solvent | GDNF in BSA, NGF in BSA | PLGA in chloroform, PDLLA in chloroform | [ | |
| Protein | Horseradish peroxidase | Potential loss of bioactivity due to conformation changes (caused by change of pH, temperature or UV light) and organic solvent interaction | Horseradish peroxidase in water | Eudragit® L100 in ethanol/DMF | [ |
| Natural extract | Gallic acid | Unstable at alkaline pH, high temperature, and in presence of light or oxygen. Restricted absorption and quick excretion from body | Gallic acid/PEO in distilled water | Zein in ethanol/water | [ |
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; DI, deionized; DMAc, dimethylacetamide; DMF, dimethylformamide; GDNF, glial cell line-derived neurotrophic factor; HFIP, hexafluoroisopropanol; NGF, nerve growth factor; PCL, poly(ɛ-caprolactone); PDLLA, poly(d,l-lactic acid); PEDF, pigmented epithelium-derived factor; PEG, poly(ethylene glycol); PEO, poly(ethylene oxide); PLGA, poly(d,l-lactic–co–glycolic acid); P(LLA-CL), poly(l-lactide–co–caprolactone); PVA, poly(vinyl alcohol); PVP, polyvinyl pyrrolidone; TFE, trifluoroethanol; UV, ultraviolet; VEGF, vascular endothelial growth factor.
Figure 9(a) TEM images of monolithic fiber (F1) and core–shell fibers with different shell thickness (F2, F3, and F4). (b) Cumulative release of ferulic acid from F1, F2, F3, and F4 in 48-h release study. Reprinted from work in [111]. Copyright 2019 with permission from Elsevier.
Figure 10(a) Alizarin Red staining (after 14 days) and (b) ALP activity assay of bone marrow-derived mesenchymal stem cells (BMMSCs) incubated in icariin/SF-PLCL fiber mats released medium. (c) Micro-computed tomography (µ-CT) images of rat calvarial defects and percentage quantification of new bone volume (d) and density (e) after 3-month fiber mats implantation. ICA denotes icariin/SF-PLCL core–shell fiber mats while SF indicates SF-PLCL fiber mats without incorporated icariin. Reprinted from work in [39]. Copyright 2017 with permission from Nature Publishing Group.
Figure 11Schematic illustration describing the effect of different pH on drug distribution during electrospinning at (a) pH 6.2 and (b) pH 8.3. Reprinted from work in [209]. Copyright 2017 with permission from Elsevier.
Figure 12SEM images of PEO/PLA-silica nanoparticles (a) prior annealing, (b) post 30 minutes annealing, and (c) after 30 min ultrasound sonication. (d) Release profiles of rhodamine B which influenced by annealing and ultrasonication. Blue dashed line represents the point where 30 min sonication was applied. Reprinted from work in [106]. Copyright 2016 with permission from Elsevier.
Figure 13(a) Schematic diagram illustrating on-demand drug release triggered by NIR light. (b) Temperature curves of PLGA hollow fibers containing DOX and FITC-BSA as a function of time under on–off action of NIR light with varying power density. (c) Cumulative release profiles of DOX and FITC-BSA under on–off switching of NIR light. Black and grey arrow represents the point where NIR light was switched on and off, respectively. Reprinted from work in [118]. Copyright 2019 with permission from Elsevier.